Last Updated: June 4, 2026

XACDURO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xacduro, and what generic alternatives are available?

Xacduro is a drug marketed by Entasis Therap and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in XACDURO is durlobactam sodium; durlobactam sodium; sulbactam sodium. One supplier is listed for this compound. Additional details are available on the durlobactam sodium; durlobactam sodium; sulbactam sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Xacduro

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for XACDURO?
  • What are the global sales for XACDURO?
  • What is Average Wholesale Price for XACDURO?
Summary for XACDURO
US Patents:0
Applicants:1
NDAs:1
Drug Prices: Drug price information for XACDURO
What excipients (inactive ingredients) are in XACDURO?XACDURO excipients list
DailyMed Link:XACDURO at DailyMed
Drug patent expirations by year for XACDURO
Drug Prices for XACDURO

See drug prices for XACDURO

US Patents and Regulatory Information for XACDURO

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Entasis Therap XACDURO (COPACKAGED) durlobactam sodium; durlobactam sodium; sulbactam sodium POWDER;INTRAVENOUS 216974-001 May 23, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Entasis Therap XACDURO (COPACKAGED) durlobactam sodium; durlobactam sodium; sulbactam sodium POWDER;INTRAVENOUS 216974-001 May 23, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Entasis Therap XACDURO (COPACKAGED) durlobactam sodium; durlobactam sodium; sulbactam sodium POWDER;INTRAVENOUS 216974-001 May 23, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Entasis Therap XACDURO (COPACKAGED) durlobactam sodium; durlobactam sodium; sulbactam sodium POWDER;INTRAVENOUS 216974-001 May 23, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links